Drug intelligence / Profile preview

STN-001

Development stage: Preclinical
Lead developer: Synthetic Design Lab
Modality: Small Molecules

Overview

STN-001 is a preclinical-stage small molecule metabolic modulator being developed by Synthetic Design Lab for the treatment of obesity. The compound was discovered and optimized using the company's generative AI platform, which focuses on the design of novel chemical entities for metabolic diseases. STN-001 is intended to address metabolic dysfunction and promote weight loss, representing the lead program in the developer's pipeline. As of 2024, the specific biological target of STN-001 has not been publicly disclosed, and the program remains in the discovery and preclinical validation phase.

Beyond the preview

Go deeper on STN-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STN-001.

Explore the full profile